Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1572-0241.2001.03579.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Botulinum toxin therapy in Parkinson disease-related lower limb dystonia. An 8 year retrospective review.
Clin Park Relat Disord
June 2024
New York Medical College, Valhalla, NY, USA.
Background: Lower extremity dystonia (LED) is a frequent complication of Parkinson disease (PD). Treatment with botulinum neurotoxinA (BoNTA) over 8 years was retrospectively reviewed.Cases14 patients with LED received an average of 3.
View Article and Find Full Text PDFCost-Effectiveness Analysis of Family-Based Treatment With Additional Home Treatment for Adolescent Anorexia Nervosa.
Eur Eat Disord Rev
January 2025
Department of Child and Adolescent Psychiatry, University of Zurich, Zurich, Switzerland.
Objective: Family-based treatment (FBT) is promising for treating adolescents with anorexia nervosa, but long-term remission rates are modest. Home treatment (HT) as a supplement to FBT aims to enhance sustainability and effectiveness by supporting recovery within the family. This study compares the cost-effectiveness of FBT alone versus FBT with additional HT for adolescents with anorexia nervosa.
View Article and Find Full Text PDFReconsidering remission in recurrent late-life depression: clinical presentation and phenotypic predictors of relapse following successful antidepressant treatment.
Psychol Med
January 2025
Department of Psychiatry, University of Illinois-Chicago, Chicago, IL, USA.
Background: Late-life depression (LLD) is characterized by repeated recurrent depressive episodes even with maintenance treatment. It is unclear what clinical and cognitive phenotypic characteristics present during remission predict future recurrence.
Methods: Participants (135 with remitted LLD and 69 comparison subjects across three institutions) completed baseline phenotyping, including psychiatric, medical, and social history, psychiatric symptom and personality trait assessment, and neuropsychological testing.
The TL1A inhibitors in IBD: what's in the pot?
Expert Rev Gastroenterol Hepatol
January 2025
IBD Center, Gastroenterology Unit, Rho Hospital, ASST Rhodense, Rho, Italy.
Introduction: Inflammatory bowel diseases (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), present ongoing challenges despite advances in pathophysiological understanding and therapeutic options. Current therapies often fail to achieve sustained remission, necessitating exploration of novel treatment targets.
Areas Covered: This review explores the role of Tumor Necrosis Factor-like cytokine 1A (TL1A) and its receptor DR3 in IBD pathogenesis, detailing their involvement in mucosal homeostasis and immune modulation.
Medication adherence in rheumatoid arthritis: implications for cardiovascular disease risk and strategies to address in U.S. Veterans.
Expert Rev Pharmacoecon Outcomes Res
January 2025
Department of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.
Introduction: Rheumatoid arthritis (RA) is a systemic inflammatory disease associated with an increased risk of cardiovascular disease (CVD) and premature mortality. The risk of CVD is closely associated with RA disease activity, and achieving RA remission using disease-modifying anti-rheumatic drugs (DMARDs) can significantly mitigate this risk. However, despite the availability of highly effective DMARDs, many veterans fail to achieve sustained RA remission.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!